David V Gauvin1, Theodore J Baird. 1. Safety Pharmacology, MPI Research, Inc, Mattawan, MI 49071-9399, United States. david.gauvin@mpiresearch.com
Abstract
INTRODUCTION: The objective of this study was to establish a functional observational battery that provided a basic neurological and behavioral assessment fully compliant with requisite governmental regulatory guidelines. METHODS: Accredited Laboratory Animal Technicians (ALAT) were trained to conduct neurobehavioral assessments in rhesus monkeys prior to and following vehicle (po), 3.2 mg/kg amphetamine (po) and 5.6 mg/kg ketamine (im) administrations. The observational battery was designed to be compliant with the goals of standard veterinary neurological examinations and federal and international regulatory guidelines related to neurotoxicity safety assessments. RESULTS: A complete neurobehavioral assessment that: 1) was safe for both non-human primate and the animal technicians conducting the assessments, 2) that examined both autonomic and central nervous system functions and, 3) that easily discriminated between the hallmark behavioral pharmacology characterizing respective psychostimulant, dissociative anesthetic, and "normal" (vehicle). DISCUSSION: We believe that these procedures provide safe, effective methodology reflecting contemporary industry's preferred practices for measuring such basic neurobehavioral functioning under the ICH, EPA, and FDA guidelines, and which is amenable to routine use within the context of efficacy, safety pharmacology, and toxicological investigations.
INTRODUCTION: The objective of this study was to establish a functional observational battery that provided a basic neurological and behavioral assessment fully compliant with requisite governmental regulatory guidelines. METHODS: Accredited Laboratory Animal Technicians (ALAT) were trained to conduct neurobehavioral assessments in rhesus monkeys prior to and following vehicle (po), 3.2 mg/kg amphetamine (po) and 5.6 mg/kg ketamine (im) administrations. The observational battery was designed to be compliant with the goals of standard veterinary neurological examinations and federal and international regulatory guidelines related to neurotoxicity safety assessments. RESULTS: A complete neurobehavioral assessment that: 1) was safe for both non-human primate and the animal technicians conducting the assessments, 2) that examined both autonomic and central nervous system functions and, 3) that easily discriminated between the hallmark behavioral pharmacology characterizing respective psychostimulant, dissociative anesthetic, and "normal" (vehicle). DISCUSSION: We believe that these procedures provide safe, effective methodology reflecting contemporary industry's preferred practices for measuring such basic neurobehavioral functioning under the ICH, EPA, and FDA guidelines, and which is amenable to routine use within the context of efficacy, safety pharmacology, and toxicological investigations.
Authors: Rhonda Pung MacAllister; Cynthia M Lester McCully; John Bacher; Marvin L Thomas; Rafael Cruz; Solomon Wangari; Katherine E Warren Journal: Comp Med Date: 2016 Impact factor: 0.982
Authors: Cynthia M Lester McCully; John Bacher; Rhonda P MacAllister; Emilie A Steffen-Smith; Kadharbatcha Saleem; Marvin L Thomas; Rafael Cruz; Katherine E Warren Journal: Comp Med Date: 2015-02 Impact factor: 0.982
Authors: Malcolm Lane; D'Arice Carter; Joseph D Pescrille; Yasco Aracava; William P Fawcett; G William Basinger; Edna F R Pereira; Edson X Albuquerque Journal: J Pharmacol Exp Ther Date: 2020-08-05 Impact factor: 4.030
Authors: Julie A Marusich; Kateland R Antonazzo; Jenny L Wiley; Bruce E Blough; John S Partilla; Michael H Baumann Journal: Neuropharmacology Date: 2014-03-02 Impact factor: 5.250
Authors: M A Basso; S Frey; K A Guerriero; B Jarraya; S Kastner; K W Koyano; D A Leopold; K Murphy; C Poirier; W Pope; A C Silva; G Tansey; L Uhrig Journal: Neuroimage Date: 2020-12-24 Impact factor: 6.556